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Abstract
Background The signiﬁcance of pre-operative body composition has recently attracted much attention in various diseases.
However, cut-off values for these parameters remain undetermined, and these factors are not currently included in selection
criteria for recipients of living donor liver transplantation (LDLT).
Methods Using computed tomography of 657 donors for LDLT, skeletal muscle mass, muscle quality, and visceral adiposity
were evaluated by using skeletal muscle mass index (SMI), intramuscular adipose tissue content (IMAC), and
visceral-to-subcutaneous adipose tissue area ratio (VSR). Sex-speciﬁc cut-offs for SMI, IMAC, and VSR were determined, and cor-
relations with outcomes after LDLT in 277 recipients were examined with the aim of establishing new selection criteria for LDLT.
Results On the basis of younger donor data, we determined sex-speciﬁc cut-off values for low SMI, high IMAC, and high VSR
(mean ± 2 standard deviations). Patients with all three factors showed the lowest survival rate after LDLT (1 year survival rate,
41.2%; P < 0.001). On multivariate analysis, low SMI (P = 0.002), high IMAC (P = 0.002), and high VSR (P = 0.001) were
identiﬁed as independent risk factors for mortality after LDLT. Based on these ﬁndings, we have excluded patients showing
all three factors (low SMI, high IMAC, and high VSR) as candidates for LDLT since October 2016.
Conclusions Using cut-off values determined from healthy donors, we have established new selection criteria for LDLT in-
cluding body composition, which should improve post-transplant outcomes.
Keywords Cut-off values; Intramuscular adipose tissue content; Liver transplantation; Sarcopenia; Skeletal muscle mass index;
Visceral-to-subcutaneous adipose tissue area ratio
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Introduction
Sarcopenia is characterized by age-related progressive and
generalized decline in skeletal muscle mass and muscle
strength and has been accepted worldwide as a new geriatric
syndrome.1 Recent studies have reported signiﬁcant associa-
tions between sarcopenia and poor outcomes in various
diseases.2–7 In the ﬁeld of liver transplantation (LT), our
recent studies have demonstrated that pre-operative low
muscularity (low muscle mass and low muscle quality) shows
a close correlation with post-transplant mortality.8,9 On the
other hand, high visceral adiposity calculated as the
visceral-to-subcutaneous adipose tissue area ratio (VSR) has
been reported as a useful predictor of poor outcomes in
several cancers.10–12 However, these body compositions have
not been included in the current selection criteria for recipi-
ents for LT, because the method for measuring muscularity
and visceral adiposity varies between investigations and
because universally accepted cut-off values for these factors
remain undetermined.
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The European Working Group on Sarcopenia in Older
People has proposed that measuring and evaluating muscle
mass, muscle strength, and physical performance are neces-
sary in order to diagnose sarcopenia.1 Among various
imaging modalities, such as dual-energy X-ray absorptiome-
try, computed tomography (CT), magnetic resonance
imaging, and bioimpedance analysis, CT seems the best
suited to measuring skeletal muscle mass in clinical settings,
particularly in the surgical ﬁeld, as CT is usually performed
as part of the pre-operative work-up and during follow-up.
Although several studies from Western countries have
proposed different cut-offs for low skeletal muscle mass as
calculated from CT,2,3,5 such values would differ from those
in Asian populations, due to general differences in character-
istics such as body size, lifestyles, and other factors. We
have previously established new diagnostic criteria for low
skeletal muscle mass by using the psoas muscle mass index
from healthy young Asian adults, which was adopted in the
Japan Society of Hepatology guidelines for sarcopenia in
liver disease.13,14 However, it is usual for evaluating skeletal
muscle mass to investigate all skeletal muscle areas at the
third lumbar vertebra (L3) level, not only psoas muscle
areas.15 In addition, no studies have established cut-off
values for evaluating muscle quality and visceral adiposity
in a healthy general population.
The present study evaluated body composition including
skeletal muscle mass, muscle quality, and visceral adiposity
by using CT of healthy adult donors for living donor LT (LDLT),
then established sex-speciﬁc cut-offs for these parameters.
Furthermore, the impact of these parameters on outcomes
after LDLT was investigated. On the basis of the results, we
aimed to develop more objective selection criteria for recipi-




Between April 2005 and July 2016, a total of 675 adult
(age ≥ 20 years) donors were admitted to Kyoto University
Hospital for adult or paediatric LDLT. Eighteen patients who
did not undergo pre-operative plain CT were excluded from
analysis. This retrospective study therefore analysed data
from 657 donors (331 men, 326 women) to investigate mus-
cularity and adiposity. The median age of the donors was
39 years [interquartile range (IQR), 31–52 years]. Numbers
of donors in each age decade were as follows: 20–29 years,
126 (19.2%); 30–99 years, 209 (31.8%); 40–49 years, 133
(20.2%); 50–59 years, 136 (20.7%); and ≥60 years, 53 (8.1%).
To evaluate the validity of cut-offs for body composition
parameters, we investigated data from patients who
underwent adult-to-adult LDLT. A total of 301 adult patients
underwent LDLT in our institution between January 2008
and July 2016. Of these, 24 patients who did not undergo
pre-operative plain CT at the L3 level were excluded from
analysis. Therefore, 277 patients were enrolled in this study.
Median duration of follow-up for these recipients was
26.1 months (IQR, 7.8–64.1 months). Selection criteria for
donors and recipients have been described previously.16,17
In brief, living donors must fulﬁl the following acceptance
criteria: (i) a relationship with the recipient within the third
civil degree and strong voluntary will to donate part of the
liver and (ii) no medical disorder that would signiﬁcantly
increase the perioperative risk. The exclusion criterion for liv-
ing liver donation was a planned remnant liver volume< 30%
of whole liver volume as estimated from pre-operative CT
volumetry. Exclusion criteria for recipients for LDLT were as
follows: (i) acute heart and/or renal failure, (ii) ongoing active
infection, (iii) extrahepatic malignancy, or (iv) hepatic
malignancy with major vascular invasion. All study protocols
were approved by the Ethics Committee of Kyoto University
(approval #R0061) and were conducted in accordance with
the 1996 revision of the Declaration of Helsinki.
Image analysis
All CTs were performed by using a multidetector-row CT
scanner (Aquilion 64; Toshiba Medical Systems, Tochigi,
Japan). The technical parameters for CT were tube voltage,
120 kV; detector conﬁguration, 0.5 mm × 64 rows; tube
current modulation, 0.5 s/rotation (gantry rotation); and
reconstruction thickness, 5 mm.
Using cross-sectional CT at the L3 level, skeletal muscle
and adipose tissue areas were examined by using AQUARIUS
INTUITION software (TeraRecon, San Mateo, CA). The AQUARIUS
INTUITION is an iNtuition client viewer with advanced visualiza-
tion capabilities. With this software, areas of skeletal muscle,
visceral, and subcutaneous adipose tissue can be easily and
automatically quantiﬁed by using the CT attenuation values
peculiar to these tissues. Skeletal muscle areas including
psoas, erector spinae, quadratus lumborum, transversus
abdominis, external and internal obliques, and rectus
abdominis were identiﬁed and quantiﬁed by using attenua-
tion values of 29 to 150 Hounsﬁeld units (HU) (Figure 1
A).18 Skeletal muscle mass was evaluated as the skeletal
muscle mass index (SMI) calculated by normalizing skeletal
muscle areas to the square of the patient’s height (cm2/
m2). Muscle quality was examined as intramuscular adipose
tissue content (IMAC) at the L3 level. As previously described,
IMAC was calculated by dividing the CT attenuation value of
the multiﬁdus muscles by that of subcutaneous fat (Figure 1
B).9 A higher IMAC indicates a greater amount of adipose tis-
sue within skeletal muscle and thus a lower quality of skeletal
muscle (muscle steatosis). In addition, subcutaneous and
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visceral adipose tissue areas were quantiﬁed by using
attenuation values of 190 to 30 HU (Figure 1C) and
150 to 50 HU (Figure 1D), respectively.18,19 VSR, which
indicates visceral adiposity, was calculated by dividing visceral
adipose tissue area by subcutaneous adipose tissue area.10
Analysed parameters
First, distributions of SMI, IMAC, and VSR according to sex
and donor age were evaluated by using the data from the
657 donors, then sex-speciﬁc cut-offs of these parameters
were established. Second, the overall survival rate after LDLT
was investigated in the 277 recipients classiﬁed according to
SMI, IMAC, and VSR. Moreover, prognostic factors were
analysed on the basis of the following variables: recipient
age (≥50 years vs. <50 years), donor age (≥50 years vs.
<50 years), sex (male vs. female), original disease, ABO
compatibility (identical/compatible vs. incompatible), Model
for End-stage Liver Disease (MELD) score (≥20 vs. <20),
Child-Pugh classiﬁcation (A/B vs. C), graft type (right vs. left),
graft-to-recipient body weight ratio (≥0.8% vs. <0.8%),
duration of surgery (≥12 h vs. <12 h), estimated blood loss
(≥10 L vs. <10 L), skeletal muscle mass (low SMI vs. normal
SMI), skeletal muscle quality (high IMAC vs. normal IMAC),
and visceral adiposity (high VSR vs. normal VSR). Finally, on
the basis of these results, we established new selection
criteria for recipients of LDLT.
Statistical analysis
Continuous data are presented as median (IQR) and were
non-parametrically analysed by using the Mann–Whitney
U-test. Categorical variables were compared by using the χ2
test or Fisher’s exact test, as appropriate. Correlations
between continuous variables were assessed by using
Pearson correlation coefﬁcients. Cumulative overall survival
rates were calculated by using Kaplan–Meier methods, with
differences between curves evaluated by using the log-rank
test. Any variable identiﬁed as signiﬁcant (P < 0.05) or show-
ing values of P < 0.10 on univariate analyses was considered
a candidate for multivariate Cox regression analysis, and the
results are shown as hazard ratios (HRs) with 95% conﬁdence
intervals. A value of P < 0.05 was considered signiﬁcant. All
statistical data were generated by using JMP PRO version 12
software (SAS Institute, Cary, NC) and PRISM 6 software
(GraphPad Software, La Jolla, CA).
Figure 1 Cross-sectional computed tomography at the level of the third lumbar vertebra. (A) Skeletal muscle areas were identiﬁed and quantiﬁed by
using a computed tomography attenuation value of 29 to 150 HU. (B) Computed tomography attenuation values of subfascial muscular tissue in the
multiﬁdus muscle and subcutaneous fat (four small circles) were examined to calculate IMAC. (C) Subcutaneous adipose tissue areas were quantiﬁed
by using attenuation values of 190 to 30 HU. (D) Visceral adipose tissue areas were quantiﬁed by using attenuation values of 150 to 50 HU. HU,
Hounsﬁeld units; IMAC, intramuscular adipose tissue content.
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Results
Distributions of body composition according to sex
and donor age
Skeletalmusclemass index, IMAC, and VSR differed signiﬁcantly
between men and women (P < 0.001 each) (Table 1). In addi-
tion, in both men and women, weak-to-moderate, but statisti-
cally highly signiﬁcant relationships were observed between
donor age and SMI (men: r = 0.291, P < 0.001, Figure 2A;
women: r = 0.254, P < 0.001, Figure 2B), IMAC (men:
r = 0.533, P < 0.001, Figure 3A; women: r = 0.492, P < 0.001,
Figure 3B), and VSR (men: r = 0.618, P < 0.001, Figure 4A;
women: r = 0.526, P < 0.001, Figure 4B). SMI, IMAC, and VSR
in younger donors (<50 years) thus differed signiﬁcantly from
those in older donors (≥50 years) in bothmen (P< 0.001 each;
Table 2) and women (P < 0.001 each; Table 2).
Sex-speciﬁc cut-offs for skeletal muscle mass index,
intramuscular adipose tissue content, and
visceral-to-subcutaneous adipose tissue area ratio
Based on these results, the sex-speciﬁc cut-off values of SMI
for low skeletal muscle mass were deﬁned as more than
two standard deviations (SDs) below the mean SMI of
younger donors (<50 years), resulting in cut-offs of
40.31 cm2/m2 for men and 30.88 cm2/m2 for women. Simi-
larly, high IMAC was deﬁned as more than the 2 SDs above
the mean, resulting in cut-offs of 0.358 for men and
0.229 for women, while cut-offs for VSR were 1.325 for
men and 0.710 for women.
Impact of body composition on outcomes after
living donor liver transplantation
Using the calculated cut-off values for body composition
parameters, we investigated the impact of pre-transplant
muscularity and visceral adiposity on outcomes after LDLT.
Among the 277 LDLT recipients, 55 (20.0%), 121 (43.7%),
and 83 (30.0%) patients exhibited low SMI, high IMAC, and
high VSR, respectively. The overall survival rate was signiﬁ-
cantly lower for each group of patients with low SMI
(P < 0.001), high IMAC (P < 0.001), or high VSR
(P < 0.001) compared with the respective normal groups.
In addition, low SMI, high IMAC, and high VSR contributed
to an increased risk of post-LDLT mortality in an additive
manner (Figure 5). Patients beyond all three cut-offs
(n = 17, 6.1%) showed the lowest survival rate after LDLT
(1 year survival, 41.2%; P < 0.001). A total of 70 patients
died in this follow-up period. The causes of death for 70
Table 1 Body composition classiﬁed according to sex
Body composition Male Female P value
Pre-transplant SMI
(cm2/m2) median (IQR)
52.37 (48.17 to 56.77) 39.41 (36.29 to 42.77) <0.001
Pre-transplant IMAC
median (IQR)
0.452 (0.512 to 0.401) 0.339 (0.412 to 0.281) <0.001
Pre-transplant VSR
median (IQR)
0.719 (0.502 to 1.053) 0.372 (0.268 to 0.560) <0.001
IQR, interquartile range; SMI, skeletal muscle mass index; IMAC, intramuscular adipose tissue content; VSR, visceral-to-subcutaneous
adipose tissue area ratio.
Figure 2 Correlations between SMI and donor age classiﬁed according to sex. Signiﬁcant negative relationships are observed between SMI and donor
age in both (A) men and (B) women. SMI, skeletal muscle mass index.
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patients were sepsis (n = 23), pulmonary complications
(n = 13), graft failure including antibody-mediated rejection
and chronic rejection (n = 17), cerebral bleeding (n = 8),
hepatocellular carcinoma recurrence (n = 2), and others
(n = 7). As the number of risk factors increased, signiﬁcantly
more patients died from infectious complications, such as
sepsis, biliary infection, and pneumonia (none: 1.0%, one:
10.2%, two: 32.0%, three: 47.1%; P < 0.001). Major post-
transplant complication rates (including grades III and IV of
the Dindo and Clavien classiﬁcation) and post-transplant
hospital stay were similar among four groups (P = 0.262,
P = 0.197, respectively).
Figure 3 Correlations between IMAC and donor age classiﬁed according to sex. Signiﬁcant positive relationships are observed between IMAC and do-
nor age in both (A) men (B) women. IMAC, intramuscular adipose tissue content.
Figure 4 Correlations between VSR and donor age classiﬁed according to sex. Signiﬁcant positive relationships are observed between VSR and donor
age in both (A) men and (B) women.VSR, visceral-to-subcutaneous adipose tissue area ratio.
Table 2 Body composition compared between younger (<50 years) and older (≥50 years) donors
Male
Body composition Younger Older P value
Pre-transplant SMI (cm2/m2) median (IQR) 53.38 (48.91 to 57.43) 48.33 (44.39 to 52.39) <0.001
Pre-transplant IMAC median (IQR) 0.465 (0.529 to 0.426) 0.389 (0.430 to 0.313) <0.001
Pre-transplant VSR median (IQR) 0.623 (0.448 to 0.825) 1.147 (0.883 to 1.454) <0.001
Female
Body composition Younger Older P value
Pre-transplant SMI (cm2/m2) median (IQR) 40.64 (37.89 to 44.03) 37.49 (34.39 to 40.30) <0.001
Pre-transplant IMAC median (IQR) 0.375 (0.447 to 0.313) 0.292 (0.336 to 0.222) <0.001
Pre-transplant VSR median (IQR) 0.323 (0.232 to 0.421) 0.610 (0.401 to 0.858) <0.001
IQR, interquartile range; SMI, skeletal muscle mass index; IMAC, intramuscular adipose tissue content; VSR, visceral-to-subcutaneous ad-
ipose tissue area ratio.
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Risk factors for poor survival after living donor liver
transplantation
Univariate Cox regression analysis identiﬁed that left lobe
graft (P = 0.030), pre-operative low SMI (P < 0.001),
pre-operative high IMAC (P < 0.001), and pre-operative high
VSR (P < 0.001) were all signiﬁcant risk factors for post-LDLT
mortality (Table 3). Multivariate analysis identiﬁed
pre-operative low SMI (HR = 2.355, P = 0.002), high IMAC
(HR = 2.179, P = 0.002), and high VSR (HR = 2.373,
P = 0.001) as poor prognostic factors after LDLT (Table 3).
Based on these results, we have excluded patients beyond
all three cut-offs (low SMI, high IMAC, and high VSR) as
candidates for LDLT since October 2016.
Discussion
Liver transplantation is currently the only curative treatment
providing a chance of long-term survival among patients with
end-stage liver disease, advanced hepatocellular carcinoma,
or acute liver failure.20 Advances in surgical techniques,
perioperative management, organ preservation, and immuno-
suppression have dramatically improved patient survival after
LT in the last few decades, and the number of LT candidates is
now steadily growing.21,22 However, despite such advances,
some patients still exhibit poor prognosis after LT, and we con-
sidered that some risk factors for poor outcomes were not
reﬂected by the current selection criteria for LT. The MELD
scoring system is currently the most widely accepted method
for predictingmortality among patients awaiting LT.23 Although
MELD score is calculated by using the three objective parame-
ters of international normalized ratio of prothrombin time, se-
rum bilirubin, and serum creatinine, the predictive ability of
MELD score for post-LT outcomes remains controversial.21,24–
27 Proper extraction of risk factors for death after LT is thus ur-
gently needed to enable the establishment of objective and uni-
versal selection criteria. Based on our previous study,8 we
added a new indication of ‘patients who can walk unaided’ to
our selection criteria for LT in 2013, resulting in better outcomes
after LDLT. Although this new indication has signiﬁcantly im-
proved post-transplant outcomes in our institution,more objec-
tive and universal selection criteria that include sarcopenic
factors should be established.
Several Japanese studies have proposed cut-offs to deﬁne
low skeletal muscle mass by using CT.14,28 However, Nishikawa
et al. evaluated skeletal muscle mass in patients with liver
cirrhosis, not in the general population,14 while the other study
used a small cohort of 45 healthy adults to investigate the rela-
tionship between skeletal muscle area and body surface.28 In
addition, no studies have investigated muscle steatosis and
visceral adiposity to establish cut-offs by using data from a
general healthy population. Body compositions differ signiﬁ-
cantly between men and women. The present study also
showed that SMI and VSR were signiﬁcantly higher in men,
and IMAC was signiﬁcantly lower in men compared with that
inwomen (P< 0.001 each). In addition, a continuousworsening
of muscularity and visceral adiposity is generally seen with the
ageing process. This change in body compositions has been
shown to become pronounced around 50 years old, with faster
progression noted after 60 years old.29,30 In the present study,
all body compositions (SMI, IMAC, and VSR) in younger donors
(<50 years) were signiﬁcantly better than those in older donors
(≥50 years) in both men (P < 0.001 each) and women
(P < 0.001 each). On the basis of these ﬁndings, we took into
consideration these two key factors of sex and age to establish
optimal cut-offs for the three body compositions. To the best of
our knowledge, the present study is the ﬁrst to evaluate muscu-
larity and visceral adiposity by using CT in a large number of
healthy Asian adults and to establish cut-offs for these parame-
ters to deﬁne the low muscularity and high visceral adiposity.
Similar to our previous study,8,9 when using the new cut-
offs, patients with low muscle mass and high muscle steatosis
exhibited lower survival rates than the respective normal
groups (P < 0.001 each). In addition, the overall survival rate
was signiﬁcantly lower in patients with high visceral adiposity
than in those with normal VSR (P < 0.001). SMI, IMAC, and
VSR were independent of each other, and no signiﬁcant rela-
tionships were seen among these three factors (data not
shown). Therefore, based on multivariate analysis investigat-
ing risk factors for post-LDLT mortality, we considered that
incorporation of all three factors into new selection criteria
for LT recipients was appropriate. The survival rate after LDLT
Figure 5 Overall survival rates in patients classiﬁed by number of body
composition variables. Overall survival rates after LDLT decreased signif-
icantly with an increasing number of prognostic body composition factors
(low SMI, high IMAC, and high VSR) (P < 0.001). IMAC, intramuscular ad-
ipose tissue content; LDLT, living donor liver transplantation; SMI, skele-
tal muscle mass index; VSR, visceral-to-subcutaneous adipose tissue area
ratio.
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gradually declined with increases in the number of risk
factors (low SMI, high IMAC, and high VSR) (Figure 5).
One-year survival rates among patients beyond none, one,
two, or three of these cut-offs were 98.0%, 78.3%, 59.7%,
and 41.2%, respectively. Based on these results, although
the number of patients meeting all three factors was small
(n = 17, 6.1%), we considered that these patients, showing
a 1 year survival rate below 50%, should be excluded as can-
didates for LDLT. In October 2016, we added this objective in-
dication to our selection criteria for recipients for LDLT,
excluding patients meeting all three of low SMI, high IMAC,
and high VSR. However, these parameters might be able to
Table 3 Univariate and multivariate analyses of prognostic factors for post-transplant survival
Variable Univariate Multivariate
HR 95% CI P Value HR 95% CI P Value
Recipient age (years)
<50 (n = 97) 1.000 (referent)
≥50 (n = 180) 0.699 0.436-1.136 0.146
Donor age (years)
<50 (n = 162) 1.000 (referent)
≥50 (n = 115) 1.134 0.703-1.815 0.601
Sex
Male (n = 134) 1.000 (referent)
Female (n = 143) 1.136 0.711-1.828 0.594
Original disease
HCC (n = 90) 1.000 (referent)
HBV or HCV-associated LC (n = 50) 1.050 0.527-2.016 0.886
PBC or PSC (n = 49) 1.445 0.750-2.717 0.265
Others (n = 88) 0.751 0.395-1.400 0.369
Period of LDLT
2008-2010 (n = 130) 1.000 (referent)
2011-2015 (n = 147) 0.842 0.519-1.360 0.481
ABO compatibility
Identical/compatible (n = 199) 1.000 (referent) 1.000 (referent)
Incompatible (n = 78) 1.616 0.982-2.605 0.059 1.651 0.995-2.687 0.052
MELD score
<20 (n = 179) 1.000 (referent) 1.000 (referent)
≥20 (n = 98) 1.564 0.970-2.502 0.067 1.347 0.822-2.189 0.235
Child-Pugh classiﬁcation
A, B (n = 99) 1.000 (referent)
C (n = 178) 1.025 0.634-1.695 0.920
GRWR (%)
<0.8 (n = 87) 1.000 (referent)
≥0.8 (n = 190) 0.926 0.544-1.522 0.768
Graft type
Right (n = 157) 1.000 (referent) 1.000 (referent)
Left (n = 120) 1.684 1.053-2.709 0.030 1.103 0.669-1.824 0.701
Splenectomy
Yes (n = 171) 1.000 (referent)
No (n = 106) 1.115 0.680-1.797 0.661
PVP (mmHg)
<15 (n = 223) 1.000 (referent)
≥15 (n = 54) 1.576 0.897-2.642 0.110
Operative time (hour)
<12 (n = 53) 1.000 (referent)
≥12 (n = 224) 0.683 0.408-1.201 0.178
Operative blood loss (L)
<10 (n = 193) 1.000 (referent)
≥10 (n = 84) 0.820 0.473-1.365 0.455
Preoperative SMI
Normal (n = 222) 1.000 (referent) 1.000 (referent)
Low (n = 55) 3.084 1.883-4.964 <0.001 2.355 1.399-3.907 0.002
Preoperative IMAC
Normal (n = 156) 1.000 (referent) 1.000 (referent)
High (n = 121) 2.641 1.633-4.369 <0.001 2.179 1.336-3.632 0.002
Preoperative VSR
Normal (n = 194) 1.000 (referent) 1.000 (referent)
High (n = 83) 3.496 2.185-5.643 <0.001 2.373 1.441-3.939 0.001
CI, conﬁdence interval; GRWR, graft-to-recipient body weight ratio; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis
C virus; HR, hazard ratio; IMAC, intramuscular adipose tissue content; LC, liver cirrhosis; LDLT, living donor liver transplantation; MELD,
Model for End-stage Liver Disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; PVP, portal venous pressure; SMI,
skeletal muscle mass index; VSR, visceral-to-subcutaneous adipose tissue area ratio.
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be improved with the aid of pre-transplant nutritional inter-
vention and rehabilitation, and outcomes in such cases have
yet to be fully investigated. Further prospective evaluations
for the validity of new criteria are needed.
The mechanisms by which low muscularity and visceral
adiposity adversely affect post-transplant mortality are not
yet fully understood. Skeletal muscle loss with increasing
adipose tissue in muscles results in the synthesis and secre-
tion of pro-inﬂammatory adipokines and declines in myokine
concentrations.31 This imbalance between adipokines and
myokines in older adults or sarcopenic populations has been
shown to lead to immunosenescence, particularly of the
natural killer lymphocytes involved in innate immunity.32 On
the other hand, visceral adiposity paradoxically impairs
immune function by altering leukocyte counts, as well as
cell-mediated immune responses, although excessive adipose
tissue activates various kinds of immune cells through
increases in leptin and decreases in adiponectin.33 On the
basis of these ﬁndings, we speculate that low muscularity
and visceral adiposity induce an inﬂammatory microenviron-
ment through imbalances between adipokines and other
cytokines, which could impair immune function and increase
mortality risk.
The ﬁndings of this study should be considered in light of
several limitations. It is necessary to consider whether the
use of 2 SDs beyond the mean of younger donors was ade-
quate in setting cut-offs for SMI, IMAC, and VSR. In our pre-
vious studies,9,34–36 cut-offs for body composition were
based on receiver operating characteristic curves. Although
the use of receiver operating characteristic curves provides
a more accurate and objective method than the use of SDs
for designing cut-offs, these values differ markedly between
study populations. Therefore, to avoid this potential problem
in using data from healthy adults, the present study aimed to
establish optimal cut-offs that could be universally applied to
other research into body composition. A previous study
deﬁned sex-speciﬁc cut-offs for low skeletal muscle mass as
more than 2 SDs below the means of young adults.37 In addi-
tion, the Asian Working Group for Sarcopenia has also recom-
mended using 2 SDs below the mean muscle mass of a young
reference group or the lower quintile when determining
cut-offs.38 In the present study, SMI, IMAC, and VSR differed
signiﬁcantly between younger (<50 years) and older
(≥50 years) donors. We therefore decided to deﬁne donors
<50 years old as the reference group and to use these values
to determine cut-offs.
In conclusion, the present study is the ﬁrst to evaluate
muscularity and visceral adiposity by using CT in a large
number of healthy Japanese individuals and to establish opti-
mal cut-offs for these parameters to deﬁne low muscularity
and high visceral adiposity. Furthermore, using these cut-offs,
we investigated risk factors for post-LDLT mortality and
extracted the group that exhibited the poorest prognosis af-
ter LT, leading to the establishment of our new selection
criteria for recipients of LDLT.
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